Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.

Researchers got together at the ISMB/ECCB conference to create, clean up, and organize Wikipedia articles on biomedical informatics.

Going forward, the company will focus on its wholly owned subsidiary Medicinal Genomics Corporation, which conducts cannabis genetics research.

The National Coordinator for Health IT sees long-term potential in APIs for secure transfer of clinical and genomic data, but it's not quite there yet on the genomic side.

The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.

Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.

That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:

· Why quality control is so challenging for NGS labs

· How reference materials may be the key to quality control

· The 9 key characteristics of sufficient NGS reference materials

· How to use QC metrics to monitor the health of your NGS assays

What’s been holding back more widespread adoption of liquid biopsy testing?

Lack of adequate circulating tumor DNA reference materials for developing and measuring safe, accurate and reproducible assays has been a challenge for clinical labs

Liquid biopsies are poised to revolutionize cancer diagnosis and therapy, but until now, advances in diagnostic technology - particularly at the low end of the sample input and sensitivity spectrum - have been hampered by the lack of ability of labs to reproducibly measure and assess the assay’s performance.